{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:28:35Z","timestamp":1793996915786,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41591-021-01510-7","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T13:38:04Z","timestamp":1633354684000},"page":"1789-1796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB\u2013IVM1a melanoma: a randomized, open-label, phase 2 trial"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"R.","family":"Dummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Gyorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hyngstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Conry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Demidov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Treichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Radcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. S.","family":"Gorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Faries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"1510_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","volume":"26","author":"JM Versluis","year":"2020","unstructured":"Versluis, J. M., Long, G. V. & Blank, C. U. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat. Med. 26, 475\u2013484 (2020).","journal-title":"Nat. Med."},{"key":"1510_CR2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1470-2045(19)30377-8","volume":"20","author":"B Helmink","year":"2019","unstructured":"Helmink, B. & Wargo, J. A. Neoadjuvant therapy for melanoma: is it ready for prime time? Lancet Oncol. 20, 892\u2013894 (2019).","journal-title":"Lancet Oncol."},{"key":"1510_CR3","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","volume":"25","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U. & Teng, M. W. L. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin. Cancer Res. 25, 5743\u20135751 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1510_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Melanoma, v.3 (National Comprehensive Cancer Network (NCCN), https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1492 (accessed 10 April 2019)."},{"key":"1510_CR5","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R. & Keilholz, U., ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1884\u20131901 (2019).","journal-title":"Ann. Oncol."},{"key":"1510_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"19","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 19, 181\u2013193 (2018).","journal-title":"Lancet Oncol."},{"key":"1510_CR7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649\u20131654 (2018).","journal-title":"Nat. Med."},{"key":"1510_CR8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","volume":"20","author":"GV Long","year":"2019","unstructured":"Long, G. V. et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2013C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 20, 961\u2013971 (2019).","journal-title":"Lancet Oncol."},{"key":"1510_CR9","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948\u2013960 (2019).","journal-title":"Lancet Oncol."},{"key":"1510_CR10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454\u2013461 (2019).","journal-title":"Nat. Med."},{"key":"1510_CR11","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria, R. N. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the international neoadjuvant melanoma consortium. Lancet Oncol. 20, e378\u2013e389 (2019).","journal-title":"Lancet Oncol."},{"key":"1510_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301\u2013309 (2021).","journal-title":"Nat. Med."},{"key":"1510_CR13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3390\/cancers12071941","volume":"12","author":"M Garutti","year":"2020","unstructured":"Garutti, M. et al. \u2018To anticipate\u2019: neoadjuvant therapy in melanoma with a focus on predictive biomarkers. Cancers 12, 1941 (2020).","journal-title":"Cancers"},{"key":"1510_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292\u2013303 (2003).","journal-title":"Gene Ther."},{"key":"1510_CR15","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1510_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RH Andtbacka","year":"2019","unstructured":"Andtbacka, R. H. et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J. Immunother. Cancer 7, 145 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1510_CR17","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199\u20136206 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1510_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-020-00554-8","volume":"21","author":"CA Larocca","year":"2020","unstructured":"Larocca, C. A., LeBoeuf, N. R., Silk, A. W. & Kaufman, H. L. An update on the role of talimogene laherparepvec (T-VEC) in the treatment of melanoma: best practices and future directions. Am. J. Clin. Dermatol 21, 821\u2013832 (2020).","journal-title":"Am. J. Clin. Dermatol"},{"key":"1510_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119 (2017).","journal-title":"Cell"},{"key":"1510_CR20","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1510_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jaad.2017.03.025","volume":"77","author":"CJ Miller","year":"2017","unstructured":"Miller, C. J. et al. Risk factors for positive or equivocal margins after wide local excision of 1345 cutaneous melanomas. J. Am. Acad. Dermatol. 77, 333\u2013340 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1510_CR22","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","volume":"24","author":"SJ Moschos","year":"2006","unstructured":"Moschos, S. J. et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J. Clin. Oncol. 24, 3164\u20133171 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1510_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/00008390-199812000-00010","volume":"8","author":"AC Buzaid","year":"1998","unstructured":"Buzaid, A. C. et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 8, 549\u2013556 (1998).","journal-title":"Melanoma Res."},{"key":"1510_CR24","doi-asserted-by":"publisher","first-page":"8057","DOI":"10.1200\/JCO.2005.02.0958","volume":"23","author":"K Koyanagi","year":"2005","unstructured":"Koyanagi, K. et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J. Clin. Oncol. 23, 8057\u20138064 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1510_CR25","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2005.04.5344","volume":"24","author":"KD Lewis","year":"2006","unstructured":"Lewis, K. D. et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J. Clin. Oncol. 24, 3157\u20133163 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1510_CR26","doi-asserted-by":"crossref","unstructured":"Gogas, H. et al. Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB\u2013IVM1c melanoma: evidence for systemic effects in a phase II, single-arm study. Poster presented at European Society for Medical Oncology, 19\u201323 October 2018, Munich, Germany.","DOI":"10.1093\/annonc\/mdy289.002"},{"key":"1510_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","volume":"372","author":"AM Eggermont","year":"2008","unstructured":"Eggermont, A. M. et al. Adjuvant therapy with pegylated interferon alpha-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372, 117\u2013126 (2008).","journal-title":"Lancet"},{"key":"1510_CR28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Stat. Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. B Stat. Methodol."},{"key":"1510_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207\u2013210 (2002).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01510-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T04:29:11Z","timestamp":1725856151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01510-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1510"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01510-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.D. has intermittent, project-focused consulting and\/or advisory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi and Catalym outside the submitted work. D.E.G. received travel expenses and an honorarium from Amgen Inc. J.H. is a contracted reviewer for Ebix publishing (but does not deem this to be relevant to the content of the current publication). He also received travel funding from BMS and served on advisory boards for BMS and Nektar. A.C.B. served on the speaker\u2019s bureau for Cardinal Health. R.C. served on the speaker\u2019s bureau for Merck, BMS, Amgen Inc., Novartis, Array and Regeneron-Sanofi. L.D. received research grants from Novartis, consulting fees for MSD, BMS, Novartis and Roche, served on the advisory board for Novartis, and received honoraria from MSD, BMS, Novartis and Roche. E.C., A.S., S.A.T., H.R., A.A. and K.S.G. are employees of and stockholders in Amgen Inc. M.F. received consulting fees from Delcath Systems Inc. and served on the advisory board for Pulse Biosciences and Novartis. M.I.R. received honoraria from Merck and Amgen Inc., served on the advisory board for Merck and Amgen Inc., received research funding from Amgen and Provectus, and travel expenses from Merck, Amgen Inc., Provectus, Novartis and Castle Biosciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}